ABSTRACT
Human papillomavirus (HPV) testing has unequivocally demonstrated superior sensitivity for detecting cervical cancer precursors (cervical intraepithelial neoplasia grade 2 or worse [CIN2+] and grade 3 or worse [CIN3+]) compared with cervical cytology, 1,2 but specificity is limited, particularly in young women. 3 The United Kingdom currently employs HPV testing to triage equivocal cytology findings, borderline cytology 4 (equivalent to atypical squamous and endocervical cells of undetermined significance 5 ), and mild dyskaryosis 4 (equivalent to low-grade squamous intraepithelial lesion 5 ) and as a test of cure for treated CIN. We have shown previously that specificity could be improved by including genotyping for the most carcinogenic HPV types (HPV 16 and HPV 18) in the triage algorithm, 6 but it is not currently employed in the United Kingdom, and all HPV-positive women with equivocal cytology are referred to colposcopy, potentially reducing the efficiency of services and risking overtreatment. Indeed, in Northern Ireland, where women younger than 25 years still attend for cervical screening for the reasons described previously, 7 HPV triage is not endorsed because of low specificity, and repeat cytology is the recommended alternative. Arguably, this approach is not ideal as there is a risk of loss to follow-up and significant delays in the treatment of young women with high-grade cervical disease.
Furthermore, the planned switch from primary cytology to HPV primary screening in the United Kingdom by 2018 will need additional triage tests to refine risk since referral of all HPV-positive women to immediate colposcopy is not clinically warranted. 3 Cervical cytology is the proposed triage method for HPV primary screening and is currently being piloted at six sentinel sites in the United Kingdom. In general, women who test HPV-positive and who are found to have abnormal cytology (borderline cytology or worse) are referred to colposcopy, while those with normal cytology undergo repeat HPV testing at 12-month intervals. 8 The proposed algorithm also discounts the use of genotyping for HPV 16 and HPV 18, although some of the participating sites have started to include this risk-refining strategy in management pathways. 9 Findings from the pilots have demonstrated that colposcopy referral rates and the number of repeat referrals will increase, particularly in younger women. 9 Furthermore, in a German cytology/HPV cotesting pilot project (Wolfsburg), the spontaneous regression rate of HPV in cytology-negative/HPV-positive women was much lower than expected (46% regression after 12 months vs an originally expected regression rate of 60% for HPV infection). It was therefore concluded that the recommended management of repeat testing would be less effective in reducing referrals than anticipated and that detection of CIN2+ could be delayed. 10 Women may also be lost to follow-up, which is a typical problem with repeat testing.
To address the current and future management challenges posed by the limited specificity of HPV testing, additional triage options incorporating more disease-specific markers should be considered so that women can be managed according to their risk of CIN2+.
Recently, a dual-stain biomarker, CINtec PLUS cytology (Roche mtm Laboratories, Heidelberg, Germany), has emerged as a promising test to improve specificity for CIN2+ in HPV-positive women. [11] [12] [13] [14] This morphology-independent biomarker combines immunochemical detection of p16INK4a (p16) overexpression, a tumor suppressor protein and marker of transforming HPV infections, and the cell proliferation marker Ki-67. The simultaneous expression of the p16 and Ki-67 markers in the same cell should mutually exclude each other under normal physiologic conditions, and therefore coexpression can identify cells with an abnormal cell cycle.
This study evaluated the clinical utility of CINtec PLUS cytology for triaging HPV-positive results in an HPV primary screening population and in women with equivocal cytology and positive HPV triage findings, using risk rather than established clinical action thresholds to determine the most efficient management. We employed European guidelines for colposcopy referral thresholds, which are commonly recommended for CIN2+ and CIN3+ risks of more than 20% and more than 10% respectively, and for additional or early repeat testing, which is considered appropriate for CIN2+ risk between 2% and 20% and CIN3+ risk between 1% and 10%. 15, 16 
Materials and Methods

Study Population
The study population consisted of 2,473 women aged 18 to 64 years who attended for cervical screening in the Western and Belfast Health and Social Care Trust areas and is therefore representative of the Northern Ireland cervical screening population. This retrospective study included residual ThinPrep liquid-based cytology (LBC) samples (Hologic, Marlborough, MA) of borderline cytology, along with mild dyskaryosis, representing a population that underwent HPV triage of equivocal cytology (n = 1,500) and cytology samples that were representative of an HPV primary screening population (n = 973). Samples were randomly selected from the Laboratory Information Management System (LabCentre, UK) by deselecting every 10th sample (triage arm) and selecting every 30th sample (HPV primary screening arm) from the generated lists and anonymized before undergoing CINtec PLUS cytology (triage arm) or HPV testing, followed by CINtec PLUS cytology (HPV primary screening arm), respectively. Clinical details and disease ascertainment were established for the triage cases before CINtec PLUS testing. The corresponding samples were up to 2 years old. Clinical outcomes were based on punch biopsy and/or large loop excision of the transformation zone (the worst recorded outcome was used) or cervical cytology and colposcopy assessment where biopsy was not considered necessary by the colposcopist. Adjudicated histologic diagnoses made on cervical biopsy specimens or ThinPrep LBC samples obtained at colposcopy were the reference standard.
The two study arms are shown in ❚Figure 1❚. European risk thresholds for colposcopy referral or repeat testing were employed as a benchmark.
The clinical performance of CINtec PLUS triage alone and combined with HPV 16/18 genotyping and its potential to reduce immediate colposcopy referrals were evaluated. This arm also provided an estimate of the proportion of cases wherein a delayed diagnosis of prevalent CIN2+ is preventable by adopting this triage test in place of repeat cytology in women younger than 25 years.
HPV-positive women with negative or equivocal cytology were triaged with CINtec PLUS combined with HPV 16/18 genotyping to establish the potential reduction or increase in immediate colposcopy referral based on disease risks determined from the triage arm of the study ( Figure 1A ) and from published evidence, [17] [18] [19] [20] as well as for HPV-positive/negative cytology cases, determined from published evidence only. 10, 17, [21] [22] [23] Women younger than 25 years were included in this analysis as this group is still represented in the cervical screening population in parts of the United Kingdom. Disease ascertainment could not be achieved for this arm of the study as samples were anonymized before HPV primary testing.
HPV Testing
HPV testing was performed using the cobas 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA), which simultaneously detects 14 high-risk HPV (hrHPV) genotypes: 12 pooled hrHPV genotypes, HPV 16 individually, and HPV 18 individually.
CINtec PLUS Cytology
The dual immunostaining was performed on the Roche Ventana BenchMark Ultra System (Roche Molecular Systems) according to the manufacturer's instructions and as previously described. 24, 25 The presence of one or more dual-stained cervical epithelial cells was indicative of a positive CINtec PLUS cytology test result. If immunoreactivity occurred in only one but not both markers (such as brown staining for p16 only or red staining for Ki-67 only), the CINtec PLUS cytology test result was considered negative. 24 The interpretation of the immunostain did not present any major difficulties for evaluators. We previously published a comprehensive study of this aspect of the test, which concluded that CINtec PLUS cytology interpretation requires a level of skill that can be achieved with only minimal training. 25 
Statistical Analysis
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) calculations with 95% confidence intervals (CIs) were used to measure the clinical performance of CINtec PLUS cytology triage, the combination of CINtec PLUS cytology with HPV 16/18 genotyping, and HPV 16/18 genotyping alone in HPV-positive women. CIN2+ and CIN3+ end points were evaluated for each triage strategy. The absolute risks of CIN2+ and CIN3+ with 95% CIs were calculated before and after CINtec PLUS cytology triage in different HPV genotype categories (HPV 16/18 positive or 12 other hrHPV positive). For analysis of independent proportions, the χ 2 test of independence was used, and for 
Results
CINtec PLUS Cytology Triage in HPV-Positive Women With Equivocal Cytology
Study Cohort
The study cohort is shown in Figure 1A . HPV positivity was 60%, ranging from 48% in women 30 years or older to 83% in women younger than 25 years (data not shown). Samples were classified as inadequate for CINtec PLUS cytology according to the Bethesda 2001 Cervical Cytology Classification system 5 and as adopted by Roche. Clinical outcomes were available for all 875 remaining participants within the 24-month follow-up period ❚Figure 2❚. Stratified by age, the percentage of CIN2+ was 25%, 29%, and 31% and CIN3+ was 11%, 13%, and 14% in women aged 30 years or older, less than 30 years, and less than 25 years, respectively. There were no invasive cancers detected.
CINtec PLUS Positivity by Age, Clinical Outcome, and HPV Genotype Figure 2 shows CINtec PLUS positivity, which was 62%, representing a decrease in immediate colposcopy referrals of about 40%. Both age groups demonstrated an increase in positivity for the dual stain with increasing severity of outcome. All four in situ detected adenocarcinomas were also positive. In the subset of women younger than 25 years, dual-stain positivity reached 92% in CIN2 and 100% in CIN3+. There was a strong association between HPV 16/18 infection and dual-stain positivity, which was 75% compared with 56% in women with 12 other hrHPVs ( Figure 1A) .
Comparison of CINtec PLUS With HPV Genotyping Stratified by Age in Women With Equivocal Cytology
The clinical performance of CINtec PLUS triage is depicted in ❚Table 1❚ and Supplementary Table 1 (all supplemental materials can be found at American Journal of Clinical Pathology online). The 2-year sensitivity and specificity were 87% and 90% for CIN2+ and 47% and 42% for CIN3+, respectively, in all non-type-specific HPVpositive women. The subdivision of the younger age group (<25 years) demonstrated higher sensitivity than any other age category (96% for CIN2+, 100% for CIN3+). When combined with HPV 16/18 genotyping, the sensitivity of CINtec PLUS triage of the 12 other hrHPV genotypes was generally found to increase for both disease end points than separate triage of non-type-specific HPVpositive women with the exception of women younger than 25 years, where the combined approach had no effect on sensitivity. In all age groups, HPV 16/18 genotyping 
Risk of CIN2+ and CIN3+ With Various Triage Strategies in HPV-Positive Women With Equivocal Cytology
The Figure 1A) . The residual risks in women younger than 25 years were above the 1% to 2% threshold to allow a return to the normal screening interval and therefore repeat testing would be necessary, while women who tested positive had higher risks that exceeded the European threshold for immediate referral. Women younger than 25 years with equivocal cytology had risks for CIN2+ (25%) and CIN3+ (12%) that were above the threshold for immediate referral regardless of HPV status, assuming that the risk of underlying CIN2+ is negligible in HPV-negative women based on the widely acknowledged high NPV of the test. While employing HPV triage in this group, similar risks for 12 other hrHPV genotypes (24% and 12%) were found. The risk of CIN2+ in women younger than 25 years was particularly increased in CINtec PLUS-positive women compared with the risks before triage (P = .027). Notably, in this group, the residual risk of CIN3+ was nonexistent, and a risk of only 5% for CIN2+ was observed.
CINtec PLUS Cytology Triage in HPV Primary Screening
Study Cohort
HPV positivity was 16%, ranging from 9% in women 30 years or older to 41% in women younger than 25 years in the HPV primary screening cohort ( Figure 1B) . So that HPV primary screening algorithms were reflected, women who tested HPV negative did not undergo further analysis. Among the 160 HPV-positive samples, 138 were classified as negative, borderline cytology, or mild dyskaryosis and therefore qualified for CINtec PLUS triage. Of these, 12 were classified as inadequate for CINtec PLUS cytology ( Figure 1B) .
Triage Strategy for HPV-Positive Women Combining CINtec PLUS Cytology With HPV 16/18 Genotyping
❚Table 3❚ shows the management pathway for the cohort of HPV-positive women if they were managed under the current sentinel sites algorithm and compares this with an alternative triage strategy that stratifies women according to risks of CIN2+ and CIN3+ based on CINtec PLUS positivity and HPV genotype. European thresholds for referral and for additional or early repeat testing indicate that immediate referral would be limited to women with equivocal cytology who are either positive for HPV 16/18 or positive for the 12 other hrHPV genotypes and dual-stain positive. This would cause a reduction in colposcopy referrals of 24% (P = .002) overall compared with the sentinel sites pathway. A pathway that immediately refers HPV-positive women with negative cytology who triage CINtec PLUS positive would generate an overall increase in referrals of 18% (P = .0001) compared with the proposed sentinel sites algorithm.
Discussion
In the current analysis, the increase in CINtec PLUS positivity with increasing severity of clinical outcome corresponds with findings from previous studies 12, 14 and supports evidence that simultaneous detection of the tumor suppressor protein p16 and the proliferation marker Ki-67 within the same cell is indicative of HPV-related transformation of cervical epithelial cells. 26 Furthermore, the higher CINtec PLUS positivity found in women infected with HPV 16/18 compared with non-HPV 16/18 infections parallels the higher carcinogenic potential of these subtypes.
The high sensitivity of CINtec PLUS for underlying CIN2+ and CIN3+ has been reported previously, [12] [13] [14] and a population that was similar to ours reported correspondingly lower specificity, which is expected in a referral population. 12 The specificity of the dual stain in the current study was improved over HPV testing in equivocal cytology and could cut the referral rate by about 40% while identifying almost all high-grade disease.
The superior sensitivity in the subdivision of the younger age group was almost identical to previous findings, 13 suggesting that the dual stain may be particularly useful where, apart from repeat cytology, no other management options exist for those with equivocal cytology. Since most women younger than 25 years with borderline or mild cytology will test HPV positive (83% in the current study), this high level of sensitivity should be sustained even if preliminary HPV triage was omitted. Moreover, the excellent NPV (only two cases of CIN2 were missed by the dual stain) indicates that specificity would improve if this population were triaged with CINtec PLUS cytology only. The high rate of CIN2+ and CIN3+ in women younger than 25 years in the current and other studies 6, 11 highlights the risk of delayed repeat testing and exemplifies the need for a triage test with a high degree of specificity, sensitivity, and NPV in this age group. That dual-stain positivity in CIN2 and CIN3+ reached 92% and 100%, respectively, in the current study indicates that all CIN3+ and almost all CIN2+ could be detected without delay if CINtec PLUS triage replaced repeat cytology in young women.
Comparable with other studies that reported HPV genotype-specific risk of cervical disease, [17] [18] [19] [20] women who tested positive for HPV 16/18 had risks that exceeded the European threshold for immediate colposcopy, indicating that this group should have immediate referral. However, women younger than 25 years who were positive for the 12 other hrHPV genotypes had lower risks, which were also consistent with previous findings [17] [18] [19] and under European guidelines could benefit from CINtec PLUS triage. Based on the current study findings, this triage could reduce immediate colposcopy referral in this subgroup of HPV-positive women with equivocal cytology by 31%. Discounting HPV status in women younger than 25 years had almost identical risks for CIN2+ and CIN3+ as those undergoing HPV triage, suggesting that HPV testing is not useful to determine risk for either referral or further triage. However, most clinicians would prefer to further triage very young women to decrease the probability of overtreatment; therefore, HPV 16/18 genotyping and CINtec PLUS triage were also considered. Comparable to all age groups, the risks of CIN2+ and CIN3+ in the youngest women were increased with dual-stain positivity, and the PPV indicated that almost half of all high-grade disease could be detected without delay. This would entail a 66% colposcopy referral rate and similar reduction in repeat testing at 6 months based on HPV and CINtec PLUS triage-positive results, although minimal variation of the referral rate would be expected if this group forwent HPV testing as the majority will test HPV positive.
Findings from the HPV triage of the equivocal cytology arm of the current study and from published evidence 10, [17] [18] [19] [20] [21] [22] [23] provided the projected risks for primary screen HPV-positive women with equivocal cytology. Under European guidelines, this group would be managed as for those with equivocal cytology who triage HPV positive, resulting in an overall reduction in colposcopy referrals of 24% (P = .002) compared with the sentinel sites pathway. Furthermore, evidence shows that the risk estimates for women who are HPV positive with negative cytology are within the risk range for repeat testing 17, 21 ; however, triaging positive for the dual stain generates risks that exceed the 10% or 20% threshold for referral, which has the advantage of expediting the detection of CIN2+ and reducing the risk of women with underlying disease being lost to follow-up. 23 In the Wolfsburg pilot project, a delayed diagnosis of CIN2+ would have been avoided in 90% of cases with CINtec PLUS triage instead of repeat testing. 10 Findings from the current study suggest that triage would generate an 18% (P = .0001) increase in referrals compared with the proposed sentinel sites algorithm. Our proposed management of 1-year rescreen in HPVpositive women who test negative for CINtec PLUS is based on studies that have shown that the residual risk for CIN2+ and CIN3+ is not low enough to return women to the normal screening interval but not high enough to warrant immediate colposcopy referral. 10, 22, 23 While there are increases as well as reductions in colposcopy referral with the proposed management pathway, the net referral rate is still reduced by about 6%; however, the key advantage is that women at most risk will be referred immediately to
Conclusion
This study was population based within a well-organized screening program, and there was complete disease ascertainment for all cases included in the HPV triage of the equivocal cytology arm of the study. Centrally reviewed histopathology was used to determine outcomes where possible, and all CINtec PLUS slides were read by an experienced pathologist and cytotechnologists as previously described. 25 Histology review could not be undertaken in CIN2+ cases that were CINtec PLUS negative because cases were anonymized after recording outcomes and before testing. Furthermore, as the study was anonymized before HPV testing, there was no disease ascertainment in the HPV primary screening arm of the study. Further studies will be needed to assess the long-term prognostic values of positive or negative CINtec PLUS cytology results. Likewise, the relative performance of the dual stain compared with cervical cytology in young, vaccinated cohorts, with the predicted reduction in the performance of cytology as a consequence of HPV vaccination, warrants further investigation. 27 In summary, the current study has shown that CINtec PLUS can detect high-grade cervical disease in HPVpositive women with equivocal cytology with high sensitivity and specificity, which is improved over HPV testing. The high sensitivity and NPV of the dual stain were most notable in women younger than 25 years. These findings highlight the potential of CINtec PLUS to improve management pathways and to reduce unnecessary referral and possible overtreatment in HPV-positive women, particularly in HPV primary screening and where women younger than 25 years still participate in cervical screening.
